[A decade of progress in the management of dyslipidemia]

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Extensive research over the past decade, including meta-analyses and clinical trials, has solidified the understanding of LDL-c's crucial role in cardiovascular disease (CVD).
• Mendelian randomization studies further support a causal link between LDL-c levels and CVD development.

Purpose of the Study:

• To review the evidence supporting LDL-c as a primary target for cardiovascular risk reduction.
• To discuss the implications of current research on lipid management guidelines.

Main Methods:

• Meta-analyses of statin trials.
• Randomized clinical trials of ezetimibe and anti-PCSK9 antibodies.
• Mendelian randomization studies.

Main Results:

• Evidence consistently demonstrates that lower LDL-c levels are associated with reduced cardiovascular risk.
• The benefit of LDL-c reduction is continuous, with no identified threshold below which further reduction is not beneficial.
• Cardiovascular risk reduction is proportional to the absolute decrease in LDL-c concentration.

Conclusions:

• New guidelines for dyslipidemia management emphasize lowering LDL-c targets.
• The complementary use of ezetimibe and anti-PCSK9 antibodies following statin therapy is recommended for enhanced LDL-c reduction.